US010961291B2

(12) **United States Patent**
Cujec et al.

(10) **Patent No.: US 10,961,291 B2**
(45) **Date of Patent: *Mar. 30, 2021**

(54) **MODIFIED FGF-21 POLYPEPTIDES AND THEIR USES**

(71) Applicant: **AMBRX, INC.**, La Jolla, CA (US)

(72) Inventors: **Thomas P. Cujec**, San Diego, CA (US); **Roberto Mariani**, San Diego, CA (US); **Anna-Maria A. Hays Putnam**, San Diego, CA (US); **William M. Keefe**, Los Angeles, CA (US); **Nick Knudsen**, Escondido, CA (US); **Lillian Skidmore**, San Diego, CA (US); **Jason Pinkstaff**, Carlsbad, CA (US); **Vadim Kraynov**, San Diego, CA (US)

(73) Assignee: **AMBRX, INC.**, La Jolla, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **16/443,226**

(22) Filed: **Jun. 17, 2019**

(65) **Prior Publication Data**

US 2020/0031894 A1 Jan. 30, 2020

Related U.S. Application Data

(62) Division of application No. 15/953,091, filed on Apr. 13, 2018, now Pat. No. 10,377,805, which is a division of application No. 15/292,700, filed on Oct. 13, 2016, now Pat. No. 9,975,936, which is a division of application No. 14/680,543, filed on Apr. 7, 2015, now Pat. No. 9,517,273, which is a division of application No. 13/732,522, filed on Jan. 2, 2013, now Pat. No. 9,079,971, which is a division of application No. 13/051,953, filed on Mar. 18, 2011, now Pat. No. 8,383,365, which is a division of application No. 12/051,830, filed on Mar. 19, 2008, now Pat. No. 8,012,931.

(60) Provisional application No. 60/988,060, filed on Nov. 14, 2007, provisional application No. 60/921,297, filed on Mar. 30, 2007.

(51) **Int. Cl.**

C07K 14/50	(2006.01)
A61K 47/60	(2017.01)
A61K 38/18	(2006.01)
A61K 38/00	(2006.01)
A61K 45/06	(2006.01)
C12N 15/70	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 14/50*** (2013.01); ***A61K 38/1825*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 47/60*** (2017.08); ***C12N 15/70*** (2013.01); *A61K 38/00* (2013.01); *Y02A 50/30* (2018.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,968,158	A	1/1961	Ruschig et al.
3,097,242	A	7/1963	Hoehn et al.
3,454,635	A	7/1969	Weber et al.
3,501,495	A	3/1970	Beregi et al.
3,654,357	A	4/1972	Bretschneider et al.
3,668,215	A	6/1972	Plumpe et al.
3,669,966	A	6/1972	Ambrogi et al.
3,708,486	A	1/1973	Kutter et al.
3,773,919	A	11/1973	Boswell et al.
4,287,200	A	9/1981	Kawamatsu et al.
4,289,872	A	9/1981	Denkewalter et al.
4,412,989	A	11/1983	Iwashita et al.
4,414,148	A	11/1983	Jansen et al.
4,452,747	A	6/1984	Gersonde
4,485,045	A	11/1984	Regen
4,511,502	A	4/1985	Builder et al.
4,511,503	A	4/1985	Olson et al.
4,512,922	A	4/1985	Jones et al.
4,544,545	A	10/1985	Ryan et al.
4,551,433	A	11/1985	DeBoer
4,569,789	A	2/1986	Blattler et al.
4,572,912	A	2/1986	Yoshioka et al.
4,619,794	A	10/1986	Hauser
4,659,839	A	4/1987	Nicolotti et al.
4,670,417	A	6/1987	Iwasaki et al.
4,671,958	A	6/1987	Rodwell et al.
4,680,338	A	7/1987	Sundoro
4,687,777	A	8/1987	Meguro et al.
4,689,406	A	8/1987	Banks et al.
4,699,784	A	10/1987	Shih et al.
4,738,921	A	4/1988	Belagaje et al.
4,755,465	A	7/1988	Gray et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU	1740283	2/1984
CA	2386517	4/2001

(Continued)

OTHER PUBLICATIONS

Sanyal A, et al. "Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial," Lancet. Dec. 22, 2018;392(10165):2705-2717.

Charles ED, et al. "Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study," Obesity (Silver Spring). Jan. 2019;27(1):41-49.

(Continued)

Primary Examiner — Elly-Gerald Stoica

(74) *Attorney, Agent, or Firm* — Robin L. Teskin; Baker, Donelson, Bearitian, Caldwell & Berkowitz, PC

(57) **ABSTRACT**

Modified FGF-21 polypeptides and uses thereof are provided.

26 Claims, 41 Drawing Sheets

Specification includes a Sequence Listing.